AstraZeneca PLC ADR (AZN) News
Filter AZN News Items
AZN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AZN News Highlights
- For AZN, its 30 day story count is now at 21.
- Over the past 9 days, the trend for AZN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- DRUG, HR and LLY are the most mentioned tickers in articles about AZN.
Latest AZN News From Around the Web
Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare GiantWeight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo Nordisk and Eli Lilly -- have seen their share prices soar this year to levels that have put them among the most valuable healthcare businesses in the world. There will almost certainly soon be more competition in this highly lucrative market, and one company that may be among those debuting a new weight-loss treatment in the next few years is AstraZeneca (NASDAQ: AZN). |
AstraZeneca fights accusations its Covid-19 jab was ‘defective’AstraZeneca is contesting accusations that its Covid-19 jab was “defective” after the drugmaker was sued for damages by a vaccine recipient who claimed to have suffered from a severe side effect. The Anglo-Swedish drugmaker, which developed the vaccine with the University of Oxford, has filed its defence in a case brought by Jamie Scott, who claimed he suffered a rare but severe type of blood clot because he took the vaccine. The lawsuit will be closely watched, in case other vaccine recipients could file more suits. |
3 No-Brainer Stocks to Buy With $1,000 Right NowA modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts. |
Elephants don’t gallop – except for AstraZenecaThe late, great investor (and Telegraph Money columnist) Jim Slater famously said that “elephants don’t gallop”. |
Here's Why Astrazeneca (AZN) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
5 Growth Stocks to Buy for 2024Forget the "Magnificent 7." |
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug DemandThrough this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio. |
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomesWILMINGTON, Del., November 20, 2023--AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. |
12 European Countries with the Best Quality of LifeIn this article, we will look into the 12 European countries with the best quality of life. If you want to skip our detailed analysis, you can go directly to the 5 European Countries with the Best Quality of Life. According to WHO’s definition of quality of life, “Quality of life is a subjective evaluation […] |
20 Most Valuable Healthcare Companies in the WorldIn this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare […] |